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Systemic anaplastic large celllymphoma (ALCL) is a CD30 posi-tive T cell lymphoma with a broad
spectrum of morphological, immune
phenotypical, and clinical
characteristics.1 Two clinicopathological
entities can be distinguished: anaplastic
lymphoma kinase (ALK) positive sys-
temic nodal ALCL and ALK negative sys-
temic nodal ALCL. ALK expression, usu-
ally the result of a t(2;5) translocation, is
related to a younger age, lower inter-
national prognostic index risk, and an
excellent prognosis.2–4 Similar to most
other lymphomas, ALCLs harbour many
non-neoplastic, in principle immune
competent, lymphocytes. In immune
competent patients, putative expression
of tumour antigens in ALCL (or any
other lymphoma) should, in principle,
elicit an antitumour immune response.
Indeed, it was shown recently that ALK
can elicit a humoral antitumour immune
response in ALK positive patients with
ALCL and that functional anti-ALK CTL
precursors are present within the periph-
eral T cell repertoire of healthy donors,
clearly indicating that ALK is a tumour
antigen.5 6 In addition, the epithelial
tumour antigen MUC1 (also known as
EMA) is highly expressed in ALK posi-
tive ALCL,7 and MUC1 has been shown
to elicit a MUC1 specific cytotoxic
immune response in haematological
malignancies.8 However, the very pres-
ence of tumour cells indicates that any
antitumour immune response, whether
humoral or cytotoxic, is apparently in-
sufficient for the elimination of tumour
cells. Assuming the presence of a specific
antitumour immune response, this indi-
cates that tumour cells have acquired
mechanisms to escape from this immune
response.
“In immune competent patients,
putative expression of tumour
antigens in anaplastic large cell
lymphoma should, in principle,
elicit an antitumour immune
response”
DO ALCLS HARBOUR TUMOUR
CELL SPECIFIC INFILTRATING
LYMPHOCYTES?
We have shown previously that activated
CTLs (that is, granzyme B and CD3/CD8
positive lymphocytes) can be detected in
all ALCLs, and that the numbers of acti-
vated CTLs vary considerably between
individual cases.2 T cells become acti-
vated only after recognition of specific
antigens, and thus the presence of
activated CTLs suggests the presence of a
specific immune response against non-
self antigens. However, there is no
definite proof that these activated CTLs
are actually directed against the tumour
cells. Importantly, it appears that pa-
tients with ALCL who have many acti-
vated CTLs show a relatively poor re-
sponse to chemotherapy and a poor
clinical outcome.2 We have explained this
phenomenon by suggesting that the
presence of a strong immune response
will result in either efficient killing of the
tumour cells, in which case no clinically
detectable tumour will occur, or in the
selection of tumour cells that have
become resistant to the cell death induc-
ing effect of CTLs. In this last case, if the
inhibition of CTL induced tumour cell
death is caused by interference with the
downstream apoptosis cascade, this will
also result in resistance to chemotherapy
induced cell death,9 and thus explain the
poor clinical outcome in patients with
many activated CTLs. However, apart
from inhibition of (CTL induced) apop-
tosis, tumour cells have many patho-
genic mechanisms by which they can
escape from a CTL mediated cell death.
In this short survey, we will discuss the
possible mechanisms by which the neo-
plastic cells of ALCL may escape from a
cytotoxic T cell mediated immune re-
sponse. However, in contrast to Hodg-
kin’s lymphoma, very few studies have
investigated the presence of immune
escape mechanisms in ALCL.
INHIBITION OF T CELL FUNCTION
Interference with antigen
presentation
An effective cytotoxic immune response
depends on an intact interaction be-
tween the T cell receptors on CTLs and
the major histocompatibility complex
(MHC) class I molecules associated with
“non-self” peptides on the target cell,
together with the appropriate costimula-
tory proteins. Downregulation of MHC
class I molecules, which could protect
the neoplastic cells against CTL recogni-
tion and killing, has been described in
various tumours, including Burkitt’s
lymphomas and Hodgkin’s disease.10–13
However, the expression of MHC class I
and II proteins and costimulatory pro-
teins has not yet been studied in ALCL.
Thus, the importance of downregulation
of these molecules as an immune escape
mechanism remains to be determined.
Inducing T cell anergy by secretion
of immune modulatory cytokines
A complex array of cytokines and chem-
okines with very different, partly oppos-
ing, functions tightly controls the im-
mune response against target cells.
Expression of immune suppressive cyto-
kines by the tumour cells may shift the
balance towards tumour tolerance in-
stead of tumour cell killing. Tumour cells
have been shown to secrete immunosup-
pressive cytokines, possibly leading to
both generalised inhibition of immune
responses and local anergy or tolerance
in tumour specific CTLs.14 Again, few
studies have been performed in ALCL,
but one study clearly demonstrated the
expression of interleukin 10 (IL-10) in
ALCL.15 IL-10 inhibits macrophages,
causes downregulation of MHC class II
molecules and cytokine synthesis by T
helper type 1 cells, and has been shown
to have a local effect on tumour cells,
rendering them insensitive to CTL medi-
ated lysis.16
Expression of FASL on neoplastic
cells
Recently, an additional strategy that pro-
vides tumour cells with an advantage
was described. Neoplastic cells of various
non-lymphoid malignancies were found
to express the FAS ligand (FASL), and to
induce apoptosis of FAS expressing T
cells infiltrating the tumours, both in
vitro and in situ.17 Thus, this offensive
strategy might provide an alternative
way to escape from a CTL mediated
immune response.18 In T cell lymphomas
(including ALCL), varying degrees of
FASL expression were found,19 20 so that
FASL expression might be involved as an
immune escape mechanism in ALCL.
DISRUPTION OF THE
INTRACELLULAR CTL INDUCED
CELL DEATH SIGNALLING
PATHWAY
CTL induced killing of target cells
After the recognition of target cells, acti-
vated CTLs induce cell death by the
induction of apoptosis. Apoptosis is an
ATP dependent physiological process
with characteristic morphological
features.21 Upon induction of apoptosis, a
cascade of proteases called caspases
(cystein containing aspartic acid specific
proteases) is activated. Once activated,
these caspases dismantle the cell by
selectively cleaving key proteins. In vitro
studies have elucidated two major apop-
tosis pathways: a caspase 9 mediated
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pathway, activated by DNA damage, and
a caspase 8 mediated pathway, activated
by ligation of specific death receptors,
including Fas. Both pathways induce
apoptosis via activation of effector cas-
pases, in particular caspase 3.22 23 CTLs
can activate these apoptosis pathways in
different ways (fig 1); namely: (1) via
direct activation of caspase 3 by
granzyme B; (2) via truncation of Bid by
granzyme B, leading to cytochrome C
release and caspase 9 mediated activa-
tion of caspase 323–26; and (3) via ligation
of FAS/CD95, a member of the tumour
necrosis factor receptor family, leading to
activation of the caspase 8 mediated
pathway.
Direct inhibition of granzyme B
function
Recently, a novel human intracellular
serine protease inhibitor (serpin), called
protease inhibitor 9 (PI9), was found to
be an efficient inhibitor of granzyme B
and to protect cells from granzyme B
mediated apoptosis.27 28 Since then, we
have detected PI9 expression in neoplas-
tic cells of several lymphomas, including
a small proportion of systemic ALCLs.29
Importantly, we found that PI9 expres-
sion in ALCL correlated with high num-
bers of tumour infiltrating activated
CTLs (unpublished data, 2002), support-
ing the notion that the presence of many
tumour infiltrating activated CTLs re-
sults in selection for CTL resistant
tumour cells.
Inhibition of downstream apoptosis
pathways
The caspase 9 pathway is regulated by
many different proteins, including mem-
bers of the bcl-2 and inhibitor of apopto-
sis protein family. Together with others
investigators, we have recently demon-
strated the expression of members of the
bcl-2 protein family in ALCL.30 31 High
expression of these proteins was found
in particular in ALK negative cases. Its
influence on the apoptosis cascade was
supported by an inverse correlation
between bcl-2 expression and numbers
of active caspase 3 positive apoptotic
cells.31 We also found that cases with
high numbers of bcl-2 expressing
tumour cells usually harboured many
activated CTLs (unpublished data, 2002),
again suggesting selection for CTL resist-
ant tumour cells.
“Inhibition of the downstream
apoptosis pathway as a putative
immune escape mechanism may
be especially relevant from a
clinical point of view, because
inhibition of apoptosis is expected
to result in decreased sensitivity to
chemotherapy”
CTL induced cell death via ligation of
FAS with concomitant activation of the
caspase 8 pathway can be inhibited by
loss of FAS expression, as has been
shown in certain T cell lymphomas,32 and
by expression of cellular FLICE inhibi-
tory protein in the tumour cells, which
will interfere with caspase 8 mediated
activation of caspase 3.33 This has not yet
been studied in ALCL.
CONCLUDING REMARKS
Although it has not yet been confirmed
that ALCLs contain tumour specific acti-
vated CTLs, it is probable that the above
mentioned immune escape mechanisms
play some role in the pathogenesis of
ALCL. Inhibition of the downstream
apoptosis pathway as a putative immune
escape mechanism may be especially rel-
evant from a clinical point of view,
because inhibition of apoptosis is ex-
pected to result in decreased sensitivity
to chemotherapy. We recently provided
evidence, although indirectly, that inhi-
bition of apoptosis may indeed be a
major determinant for a poor clinical
outcome in ALK negative patients with
ALCL.31
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We are pleased to inform authors and reviewers of the new online submission and review system at JCP. Developed by High-
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